84 related articles for article (PubMed ID: 15290397)
1. Soluble and cell-associated forms of some yet to be identified factor in transfused blood which promotes solid tumor growth in mice.
Okuyama M; Motoyama S; Saito S; Saito R; Nakamura M; Imano H; Minamiya Y; Ogawa J
Surg Today; 2004; 34(8):673-7. PubMed ID: 15290397
[TBL] [Abstract][Full Text] [Related]
2. Transfusion-related immunomodulation due to peripheral blood dendritic cells expressing the CD200 tolerance signaling molecule and alloantigen.
Clark DA; Gorczynski RM; Blajchman MA
Transfusion; 2008 May; 48(5):814-21. PubMed ID: 18298594
[TBL] [Abstract][Full Text] [Related]
3. Influence of the timing of blood transfusion on experimental tumor growth.
Francis DM; Clunie GJ
J Surg Res; 1993 Mar; 54(3):237-41. PubMed ID: 8474239
[TBL] [Abstract][Full Text] [Related]
4. Semi-allogeneic (F1) versus fully allogeneic blood transfusions: differences in their ability to induce specific immunological unresponsiveness.
Roelen DL; Dover EL; Niimi M; Young NT; Morris PJ; Wood KJ
Eur J Immunol; 1996 Jul; 26(7):1468-74. PubMed ID: 8766548
[TBL] [Abstract][Full Text] [Related]
5. Genetic immunization with the free human chorionic gonadotropin beta subunit elicits cytotoxic T lymphocyte responses and protects against tumor formation in mice.
Geissler M; Wands G; Gesien A; de la Monte S; Bellet D; Wands JR
Lab Invest; 1997 Jun; 76(6):859-71. PubMed ID: 9194861
[TBL] [Abstract][Full Text] [Related]
6. [Monitoring impact of measurement of urinary beta-human chorionic gonadotropin on orthotopic implantation model of human ovarian carcinoma in athymic nude mice].
Li J; Xing H; Gao QL; Lu YP; Wang SX; Zhang AL; Xi L; Ma D
Ai Zheng; 2002 Sep; 21(9):949-53. PubMed ID: 12508539
[TBL] [Abstract][Full Text] [Related]
7. Is immunosuppression at the tumor site mechanism of evasion of a systemic response?
Karakousis CP; Sharma S; Brooks SP
J Med; 2003; 34(1-6):3-14. PubMed ID: 17682306
[TBL] [Abstract][Full Text] [Related]
8. Studies on the induction of tolerance to alloantigens. II. The generation of serum factor(s) able to transfer alloantigen-specific tolerance for delayed-type hypersensitivity by portal venous inoculation with allogeneic cells.
Fujiwara H; Qian JH; Satoh S; Kokudo S; Ikegami R; Hamaoka T
J Immunol; 1986 Apr; 136(8):2763-8. PubMed ID: 2420865
[TBL] [Abstract][Full Text] [Related]
9. A noninvasive approach for assessing tumor hypoxia in xenografts: developing a urinary marker for hypoxia.
Nelson DW; Cao H; Zhu Y; Sunar-Reeder B; Choi CY; Faix JD; Brown JM; Koong AC; Giaccia AJ; Le QT
Cancer Res; 2005 Jul; 65(14):6151-8. PubMed ID: 16024616
[TBL] [Abstract][Full Text] [Related]
10. Growth and metastasis in allogeneic hosts. Lack of H-2-negative or somatic hybrid variant selection.
De Giovanni C; Lollini PL; Nicoletti G; Del Re B; Scotlandi K; Prodi G; Nanni P
Exp Clin Immunogenet; 1987; 4(3):153-62. PubMed ID: 3273420
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic cell therapy for a murine mammary carcinoma.
Morecki S; Yacovlev E; Diab A; Slavin S
Cancer Res; 1998 Sep; 58(17):3891-5. PubMed ID: 9731499
[TBL] [Abstract][Full Text] [Related]
12. Protection against experimental cerebral metastases of murine melanoma B16 by active immunization.
Staib L; Harel W; Mitchell MS
Cancer Res; 1993 Mar; 53(5):1113-21. PubMed ID: 8439956
[TBL] [Abstract][Full Text] [Related]
13. In vivo reexpression of H-2 antigens in B16 melanoma cells.
Lollini PL; Colombo MP; De Giovanni C; Nicoletti G; Parmiani G; Prodi G; Nanni P
Exp Clin Immunogenet; 1985; 2(1):14-23. PubMed ID: 3939971
[TBL] [Abstract][Full Text] [Related]
14. [Effects of syngeneic preserved blood cells on metastatic growth of the Lewis lung carcinoma].
Ichikura T; Tamakuma S; Ito H; Tomimatsu S; Valeri CR
Nihon Geka Gakkai Zasshi; 1991 Jun; 92(6):734-9. PubMed ID: 1886579
[TBL] [Abstract][Full Text] [Related]
15. Taurolidine improves survival by abrogating the accelerated development and proliferation of solid tumors and development of organ metastases from circulating tumor cells released following surgery.
Da Costa ML; Redmond HP; Bouchier-Hayes DJ
J Surg Res; 2001 Dec; 101(2):111-9. PubMed ID: 11735264
[TBL] [Abstract][Full Text] [Related]
16. Chemoimmunotherapy for melanoma with dacarbazine and 2,4-dinitrochlorobenzene elicits a specific T cell-dependent immune response.
Wack C; Kirst A; Becker JC; Lutz WK; Bröcker EB; Fischer WH
Cancer Immunol Immunother; 2002 Oct; 51(8):431-9. PubMed ID: 12202904
[TBL] [Abstract][Full Text] [Related]
17. Effects of hypovolemia and transfusion on tumor growth in MCA-tumor-bearing rats.
Younes RN; Rogatko A; Vydelingum NA; Brennan MF
Surgery; 1991 Mar; 109(3 Pt 1):307-12. PubMed ID: 2000562
[TBL] [Abstract][Full Text] [Related]
18. In vivo interferon regulatory factor 3 tumor suppressor activity in B16 melanoma tumors.
Duguay D; Mercier F; Stagg J; Martineau D; Bramson J; Servant M; Lin R; Galipeau J; Hiscott J
Cancer Res; 2002 Sep; 62(18):5148-52. PubMed ID: 12234977
[TBL] [Abstract][Full Text] [Related]
19. Alloantigen-induced cytotoxicity against syngeneic tumor cells: analysis at the clonal level.
Sensi M; Orosz CG; Bach FH
J Immunol; 1984 Jun; 132(6):3218-25. PubMed ID: 6202778
[TBL] [Abstract][Full Text] [Related]
20. Development of human chorionic gonadotropin subunit-beta promoter-based toxic gene therapy for testicular cancer.
Shirakawa T; Gotoh A; Zhang Z; Kao C; Chung LW; Gardner TA
Urology; 2004 Mar; 63(3):613-8. PubMed ID: 15028478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
